Advanced search
Publication Cover
Postgraduate Medicine Volume 133, 2021 - Issue 4
Submit an article Journal homepage
2,030
Views
4
CrossRef citations to date
0
Altmetric
Clinical features - Original research

Effect of a change in lasmiditan dose on efficacy and safety in patients with migraine

David B. Clemowa Eli Lilly and Company, Indianapolis, IN, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-5328-8285
ORCID Icon,
Helen M. Hochstetler
ORCID Icon,
Yan Donga Eli Lilly and Company, Indianapolis, IN, USA
,
Paula Haucka Eli Lilly and Company, Indianapolis, IN, USAORCID Iconhttps://orcid.org/0000-0002-2889-235X
ORCID Icon,
Mario F. P. Peresb Institute of Psychiatry, University of Sao Paulo, Sao Paulo, Brazil;c Hospital Albert Einstein, Sao Paulo, BrazilORCID Iconhttps://orcid.org/0000-0002-0068-1905
ORCID Icon &
Jessica Ailanid MedStar Georgetown Headache Center, Georgetown University, Washington, DC, USAORCID Iconhttps://orcid.org/0000-0001-8106-4927
ORCID Icon
Pages 449-459 | Received 11 Oct 2020, Accepted 04 Dec 2020, Published online: 17 Mar 2021

References

  • ReyvowTM (lasmiditan) tablets. [Package insert]. Eli lilly and Company; [cited 2019 Nov 6]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf
  • Tfelt-Hansen PC, Pihl T, Hougaard A, et al. Drugs targeting 5-hydroxytryptamine receptors in acute treatments of migraine attacks. A review of new drugs and new administration forms of established drugs. Expert Opin Investig Drugs. 2014 Mar;23(3):375–385.
  • Clemow DB, Johnson KW, Hochstetler HM, et al. Lasmiditan mechanism of action – review of a selective 5-HT1F agonist. J Headache Pain. 2020 Jun 10;21(1):71.
  • Kovalchin J, Ghiglieri A, Zanelli E, et al. Lasmiditan acts specifically on the 5-HT1F receptor in the central nervous system. Cephalalgia. 2016;36(1_suppl):103.
  • Labastida-Ramirez A, Rubio-Beltran E, Haanes KA, et al. Lasmiditan inhibits calcitonin gene-related peptide release in the rodent trigeminovascular system. Pain. 2020 May;161(5):1092–1099.
  • Rubio-Beltran E, Labastida-Ramirez A, Villalon CM, et al. Is selective 5-HT1F receptor agonism an entity apart from that of the triptans in antimigraine therapy? Pharmacol Ther. 2018 Jun;186:88–97.
  • Nelson DL, Phebus LA, Johnson KW, et al. Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. Cephalalgia. 2010 Oct;30(10):1159–1169.
  • Rubio-Beltran E, Labastida-Ramirez A, Haanes KA, et al. Characterization of binding, functional activity, and contractile responses of the selective 5-HT1F receptor agonist lasmiditan. Br J Pharmacol. 2019 Dec;176(24):4681–4695.
  • Vila-Pueyo M. Targeted 5-HT1F therapies for migraine. Neurotherapeutics. 2018 Apr;15(2):291–303.
  • Goadsby PJ, Wietecha LA, Dennehy EB, et al. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain. 2019 Jul 1;142(7):1894–1904.
  • Kuca B, Silberstein SD, Wietecha L, et al. Lasmiditan is an effective acute treatment for migraine: a phase 3 randomized study. Neurology. 2018 Dec 11;91(24):e2222–e2232.
  • Ashina M, Vasudeva R, Jin L, et al. Onset of efficacy following oral treatment with lasmiditan for the acute treatment of migraine: integrated results from 2 randomized double-blind placebo-controlled phase 3 clinical studies. Headache. 2019 Nov;59(10):1788–1801.
  • Krege JH, Rizzoli PB, Liffick E, et al. Safety findings from phase 3 lasmiditan studies for acute treatment of migraine: results from SAMURAI and SPARTAN. Cephalalgia. 2019 Jul;39(8):957–966.
  • Smith T, Krege JH, Rathmann SS, et al. Improvement in function after lasmiditan treatment: post hoc analysis of data from phase 3 studies. Neurol Ther. 2020 May 23. DOI:10.1007/s40120-020-00185-5.
  • Tepper SJ, Krege JH, Lombard L, et al. Characterization of dizziness after lasmiditan usage: findings from the SAMURAI and SPARTAN acute migraine treatment randomized trials. Headache. 2019 Jul;59(7):1052–1062.
  • Brandes JL, Klise S, Krege JH, et al. Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study). Cephalalgia. 2019 Oct;39(11):1343–1357.
  • Clemow DB, Baygani SK, Hauck PM, et al. Lasmiditan in patients with common migraine comorbidities: a post hoc efficacy and safety analysis of two phase 3 randomized clinical trials. Curr Med Res Opin. 2020;6:1–16.
  • Brandes JL, Klise S, Krege JH, et al. Long-term safety and efficacy of lasmiditan for acute treatment of migraine: final results of the GLADIATOR study. Cephalalgia Rep. 2020;3:2515816320958176.
  • Migraine trust virtual 2020 – oral presentations. Cephalalgia. 2020;40(1_suppl):3–17.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.